Acetazolamide Per os for Decompensation of Heart Failure

Study acronym: ORION-A
StatusCompleted
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Eligibility criteria expanded, about 25 words
    • Site details revised
  2. Primary completion date: Aug 28, 2024 to Aug 28, 2025
    • Study completion date: Sep 1, 2024 to Dec 1, 2025
    v7
  3. Primary completion date: Feb 28, 2024 to Aug 28, 2024v6
  4. Primary completion date: Aug 31, 2023 to Feb 28, 2024
    • Study completion date: Sep 30, 2023 to Sep 1, 2024
    v5
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Apr 1, 2023 to May 1, 2023v3
  2. Eligibility criteria shortened, about 4 words
    • Study description expanded, about 2 words
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main causes of chronic heart failure (CHF) are arterial hypertension and coronary artery disease, less often cardiomyopathy, pericarditis, metastatic myocardial lesions. It should be noted that up to 50% of patients have a preserved left ventricular ejection fraction (LVEF), while its prevalence is progressively increasing annually. Acute decompensation of CHF is understood as a rapid increase in the severity of clinical manifestations (shortness of breath, severe arterial hypoxemia, the occurrence of arterial hypotension), which caused urgent medical treatment and emergency hospitalization in a patient already suffering from CHF. Decompensation of CHF requires intensification of treatment in order to stabilize the patient's condition. Strengthening diuretic therapy in addition to standard therapy helps to reduce edematous syndrome.
Trial Details
NCT Number NCT05802849
Lead Sponsor Samara State Medical University
Conditions
(from sponsor)		 Chronic Heart Failure
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov